← Human Trials & Peer-Reviewed Studies
Nicotine effects on default mode network during resting state.
Plain-language guide to PMID 21331518 (2011): single-blind controlled clinical trial of Therapeutic nicotine (patch, non-peptide).
Key Facts
- PMID
- 21331518
- Journal
- Psychopharmacology
- Year
- 2011
- Study type
- Controlled Clinical Trial
- Authors
- Tanabe J et al. (7 authors)
- DOI
- 10.1007/s00213-011-2221-8
What This Study Did, in Plain Language
What Was Tested
This controlled clinical trial looks at Therapeutic nicotine (patch, non-peptide).
This study aims to determine if nicotine suppresses activity in default mode and enhances activity in extra-striate RSNs in the absence of an external visual task.
Why It Was Studied
The default mode network (DMN), one of several resting-state networks (RSN) in the brain, is thought to be involved in self-referential thought, awareness, and episodic memories.
Who Took Part
By PubMed's age tags, the people studied were adults, both men and women.
How the Study Was Run
The design is described as single-blind, placebo-controlled and crossover.
Only one side, usually the participants, was kept unaware of whether Therapeutic nicotine (patch, non-peptide) was given.
The comparison arm used a placebo, so changes seen with Therapeutic nicotine (patch, non-peptide) could be set against what happens without it.
In the crossover set-up each of the participants took both Therapeutic nicotine (patch, non-peptide) and the comparison in turn, acting as their own control.
Group independent component analysis was performed.
The DMN component was identified by spatial correlation with a reference DMN mask.
A visual attention component was identified by spatial correlation with an extra-striate mask.
Analyses were conducted using statistical parametric mapping.
What Was Measured
PubMed files the paper under topics including Brain Mapping, Magnetic Resonance Imaging, Nerve Net, Nicotine, Nicotinic Agonists and Visual Perception.
What This Means in Plain Language
The paper is a single-blind, placebo-controlled and crossover study of Therapeutic nicotine (patch, non-peptide).
The abstract goes on to report its results in about 3 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2011 (Psychopharmacology), a journal based in Germany.
More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.
Our Notes on the Compound
Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.